非小细胞肺癌（NSCLC）仍然是全球癌症死亡的主要原因。以铂为基础的化疗是标准护理，但存在毒性和耐药问题。金、钌和其他金属的金属配合物已被视为有前途的替代药物。本综述提供了关于NSCLC的金属药物的全面分析。文献计量分析揭示了对阐明机制、开发靶向治疗和协同组合的不断增长的兴趣。金属药物的分类强调了铂、金和钌化合物，以及新兴的金属。多样的机制包括DNA损伤、氧化还原调节和免疫调节。临床前研究显示在体外和体内具有细胞毒性和抗肿瘤效果，提供了概念证明。临床试验表明，铂类药物具有一定的功效，但耐药问题仍然存在。非铂金属药物具有良好的安全性，但迄今为止单一药物疗效较低。纳米粒子等药物传递方法显示出增强治疗指标的潜力。未来的方向包括优化基于金属的复合物、阐明耐药机制、生物标志物的开发和联合治疗，以充分实现金属药物在NSCLC中的潜力。版权所有 © 2023 徐、戴、毛、张、秦、郑。

Non-small cell lung cancer (NSCLC) remains a leading cause of cancer mortality worldwide. Platinum-based chemotherapy is standard-of-care but has limitations including toxicity and resistance. Metal complexes of gold, ruthenium, and other metals have emerged as promising alternatives. This review provides a comprehensive analysis of metallodrugs for NSCLC. Bibliometric analysis reveals growing interest in elucidating mechanisms, developing targeted therapies, and synergistic combinations. Classification of metallodrugs highlights platinum, gold, and ruthenium compounds, as well as emerging metals. Diverse mechanisms include DNA damage, redox modulation, and immunomodulation. Preclinical studies demonstrate cytotoxicity and antitumor effects in vitro and in vivo, providing proof-of-concept. Clinical trials indicate platinums have utility but resistance remains problematic. Non-platinum metallodrugs exhibit favorable safety but modest single agent efficacy to date. Drug delivery approaches like nanoparticles show potential to enhance therapeutic index. Future directions include optimization of metal-based complexes, elucidation of resistance mechanisms, biomarker development, and combination therapies to fully realize the promise of metallodrugs for NSCLC.Copyright © 2023 Xu, Dai, Mao, Zhang, Qin and Zheng.